Investor Relations

Jan 12, 2022

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

Stock Snapshot

Company Overview

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, maveropepimut-S (DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing maveropepimut-S as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.

Investor Contact Information

Headquarters

130 Eileen Stubbs
Suite 19
Dartmouth, Nova Scotia B3B 2C4
Canada

Corporate Office

2875 Boulevard Laurier
Delta 1, Suite 220
Québec, Québec G1V 2M2
Canada